GLP-1 receptor agonists and dual GLP-1/GIP agonists like tirzepatide show significant efficacy for type 2 diabetes and obesity, with emerging evidence for cardiovascular protection, neuroprotective benefits, and mental health improvements.
Dual agonists potentiate glycemic control and weight lossTirzepatide's dual GLP-1/GIP targeting enhances metabolic outcomes beyond single-target GLP-1 receptor agonists alone
What the researchers found
GLP-1 receptor agonists work through multiple mechanisms: stimulating insulin secretion, suppressing glucagon release, delaying gastric emptying, and reducing appetite via GLP-1 receptor activation. These agents have demonstrated significant efficacy for type 2 diabetes and obesity management.
Dual GLP-1/GIP receptor agonists like tirzepatide activate both GLP-1 and GIP receptors simultaneously, providing enhanced glycemic control, greater weight loss, and improved metabolic function compared to single-target agents. Beyond metabolic effects, emerging evidence supports cardiovascular protection, neuroprotective benefits, and positive effects on mental health for these drug classes. The review also covers advances in triple receptor agonists targeting GLP-1, GIP, and glucagon receptors.
Why it matters
GLP-1-based therapies are among the most transformative drug developments of the past decade, reshaping treatment of diabetes and obesity and now expanding into cardiovascular disease, neurodegeneration, and mental health. Understanding the differences between single, dual, and emerging triple receptor agonists is critical for clinicians and patients navigating these rapidly evolving treatment options. This review provides a timely synthesis as these drugs move into clinical use for an ever-widening range of conditions.
How the study worked
This is a comprehensive narrative review that systematically compares the mechanistic pathways, therapeutic efficacy, and safety profiles of GLP-1 receptor agonists versus GLP-1/GIP dual receptor agonists. The review integrates evidence from clinical trials across multiple therapeutic areas including diabetes, obesity, cardiovascular disease, neurological conditions, perioperative management, and neuropsychiatric outcomes.
What this study cannot tell us
As a narrative review, the paper reflects selective literature coverage rather than a systematic meta-analysis. The evidence for newer applications (neuroprotection, mental health, perioperative use) is still emerging and largely from early-stage or observational studies. Long-term safety data for dual and triple receptor agonists is limited. The review does not provide specific numerical comparisons between individual drugs within each class.
How to read the evidence
This is a narrative review synthesizing evidence from multiple clinical trials and studies. While the established efficacy for diabetes and obesity is supported by high-quality randomized controlled trials, the evidence for newer applications (neuropsychiatric, perioperative) is still emerging and of variable quality.
When this study was published
Published in 2025, this is a very current review capturing the latest developments including tirzepatide's expanded indications, emerging triple agonists, and the newest evidence for non-metabolic applications of GLP-1-based therapies.
The bigger picture
The GLP-1 receptor agonist revolution represents one of the most important developments in peptide therapeutics. From semaglutide's blockbuster success to tirzepatide's dual-receptor approach and emerging triple agonists, this drug class is rapidly expanding what peptide-based medicines can achieve. The move beyond metabolic disease into cardiology, neurology, and psychiatry could position incretin-based peptide drugs as some of the most widely prescribed medications in modern medicine.
Questions still open
- Will triple receptor agonists (GLP-1/GIP/glucagon) offer clinically meaningful advantages over dual agonists like tirzepatide?
- How significant are the neuroprotective effects of GLP-1RAs, and could they prevent or treat Alzheimer's disease?
- What is the optimal approach for patients who respond differently to GLP-1 versus GIP receptor activation?
Common questions
What is the difference between GLP-1 receptor agonists and dual GLP-1/GIP agonists?
What new uses are being discovered for GLP-1 drugs beyond diabetes and weight loss?
Read the original research
The Clinical Application of GLP-1RAs and GLP-1/GIP Dual Receptor Agonists Based on Pharmacological Mechanisms: A Review.
Drug design, development and therapy, 19, 10383-10409
Citation
Liu, Zhao; Yu, Shanshan; Jin, Xinyan; Sheng, Luguang; YanMu, Mai Re; Gao, Jie; Lu, Jun; Lei, Tao. (2025). The Clinical Application of GLP-1RAs and GLP-1/GIP Dual Receptor Agonists Based on Pharmacological Mechanisms: A Review.. Drug design, development and therapy, 19, 10383-10409. https://doi.org/10.2147/DDDT.S559919